Aβ Oligomers in Focus: Clinical Advancement of PRI-002 in Nature Communications
Just recently, Kutzsche et al. published major findings from a Phase 1b clinical trial evaluating the safety, tolerability, and pharmacokinetics of PRI-002—an investigational compound designed to disassemble toxic Aβ oligomers in Alzheimer’s disease (AD).
In this randomized, placebo-controlled trial, patients with mild cognitive impairment or early-stage AD received PRI-002 daily for 28 days. The compound was well tolerated and led to significantly improved memory performance on the CERAD word list compared to placebo.
The study employed quantitative measurements of Aβ oligomers in cerebrospinal fluid using attyloid’s sFIDA technology. Similar to the AD core biomarkers, oligomer levels showed no consistent change. This may suggest that the treatment conditions did not yet fall within a therapeutically effective window to produce measurable biomarker effects. These aspects are currently being investigated in an ongoing Phase 2 trial involving higher dosing and extended treatment duration. (NCT06182085).